About Zinc finger protein 548
Zinc finger protein 548 (ZNF548) is a protein
from Homo sapiens identified by UniProt accession
Q8NEK5, 533 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | Zinc finger protein 548 |
|---|
| UniProt accession | Q8NEK5 |
|---|
| Gene | ZNF548 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 533 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (7)
Diseases linked to this target (Open Targets).
- appendicular lean mass · score 0.20
- acute myeloid leukemia · score 0.18
- fat body mass · score 0.12
- lean body mass · score 0.07
- platelet count · score 0.07
- large cell medulloblastoma · score 0.01
- type 1 diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NEK5-F1 | alphafold | PREDICTED | 66.10 | — |
Amino-acid sequence (533 residues)
MNLTEGRVVF EDVAIYFSQE EWGHLDEAQR LLYRDVMLEN LALLSSLGSW HGAEDEEAPS QQGFSVGVSE VTASKPCLSS QKVHPSETCG PPLKDILCLV EHNGIHPEQH IYICEAELFQ HPKQQIGENL SRGDDWIPSF GKNHRVHMAE EIFTCMEGWK DLPATSCLLQ HQGPQSEWKP YRDTEDREAF QTGQNDYKCS ECGKTFTCSY SFVEHQKIHT GERSYECNKC GKFFKYSANF MKHQTVHTSE RTYECRECGK SFMYNYRLMR HKRVHTGERP YECNTCGKFF RYSSTFVRHQ RVHTGERPYE CRECGKFFMD SSTLIKHQRV HTGERPYKCN DCGKFFRYIS TLIRHQRIHT GERPYECSVC GELFRYNSSL VKHWRNHTGE RPYKCSECGK SFRYHCRLIR HQRVHTGERP YECSECGKFF RYNSNLIKHW RNHTGERPYE CRECGKAFSH KHILVEHQKI HSGERPYECS ECQKAFIRKS HLVHHQKIHS EERLVCSMNV GNSLAKTPTS LNIRDFTMEK VYH
Explore Zinc finger protein 548 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets